Evidence level: B
“短期有效、长期也有效”不是同一个东西量了两次,是两条衰减速度差两个数量级的曲线叠在一起——分不开它们,谈机制就是猜。
正文
先给结论:氡浴研究里被反复引用的两个读数——疗程结束时疼痛下降、九个月后还有优势——从来不是同一件事的两个快照。它们是两条曲线叠在一张图上:一条以小时为半衰期,一条以月为半衰期。当成一条曲线读,必然得出”疗效在缓慢消退”的错觉;真正的任务是把两条曲线的衰减常数各自拟合出来。
第一层:热量的是小时级的钟。 热疗镇痛起效快、消退也快,这是常识,但”多快”一直没被严肃拟合过。方法学上有个提醒:评估热适应的时程不能靠固定时点前后比对,因为基线选择与衰减模型形状会直接改变结论(PMID 38872315)。同一个坑在热镇痛上更深——单次热暴露的效应可能一天内归零大半,而你只在疗程前后各测一次,中间那段衰减完全看不见。
第二层:免疫量的是周级的钟。 小鼠吸入氡 2,000 Bq/m³,2 周时免疫指标没动,4 周才激活 Th1/Th2/Th17,且三者平衡未被打破,同时脾脏 SOD 降、CAT 升(PMID 35400822)。”2 周不动、4 周才动”的分量在于:免疫通道有启动延迟,而临床疗程普遍只有 3 到 4 周,正好压在起效边缘。更麻烦的是方向:同一实验里正常鼠被激活、关节炎模型鼠(SKG)被拉回正常——调控是双向的,直接否掉了”某个标志物越高越好”的追踪思路。另一条 K/BxN 模型给出的信号又换了对象:临床评分改善伴随外周血 B 细胞与 IL-5 升高,不是 Treg(PMID 35203348)。不同模型指向不同细胞,这本身就是”通道还没定”的证据。
第三层:一个算术就能定生死。 设热效应半衰期 1 天、免疫效应半衰期 90 天。停疗第 30 天,热残余是 0.5³⁰,约十亿分之一,等于零;免疫残余 0.5^(30/90),还有 79%。第 180 天免疫剩 25%,第 270 天剩 12.5%。IMuRa 试验 681 人随访九个月,疼痛与镇痛药用量仍显著优于对照(p=0.032 / p=0.007,PMID 23864139)——九个月时热残余已是十亿分之一,”还显著”本身就把热效应排除了,不需要任何中介分析。疗程结束那刻测到的总效应里含热的大量份额,这部分本来就不该留到第九个月。效应从 0.7 个标准差掉到 0.2,正确读法是”热的那部分按时退场”,不是”疗效在衰减”。
第四层:最锋利的一刀。 83 名强直性脊柱炎患者在 Bad Gastein 接受 3 至 4 周含低剂量氡的矿坑疗法,活性 TGF-β1 从 77 升到 1,096 pg/ml;按疼痛是否缓解分组,应答者升 17 倍(96→1,654),非应答者升 7 倍(53→402,PMID 16810484)。非应答者也涨了七倍。若 TGF-β1 真是”氡→免疫→镇痛”链条上的中介,疼痛没改善的人不该出现同样方向。它涨了,说明它更像伴随反应,不是传话的那一环。把免疫标志物当替代终点,会在这里翻车。
第五层:双臂设计根本拆不开。 “氡浴 vs 热浴”看起来干净,但氡必须靠热浴递送——热不是可剔掉的对照,而是氡的载体。当一个因子的水平依赖另一因子的存在,两者是交互,不是中介。中介分析假设路径可加,交互则明确说不可加。用双臂数据做中介,等于默认了正在被质疑的前提。
第六层:可拆的结构已经出现了。 RAD-ON02 试验里,热浴与氡浴都减少了破骨细胞分化与骨片吸收面积,氡浴更明显;但只有氡浴组出现 RANKL 显著下降与 Treg 显著上升,Th17 不变(PMID 38292488)。正确表述是“共有的热通道 + 氡独有的免疫增量”,不是”氡有效、热无效”。要检验它,得用热×氡的析因结构,只有析因才能把主效应与交互项分开估。
第七层:真要做中介,规矩是先说清时点。 报告规范要求写出因果假设、中介与结局各自的测量时点、以及两者间是否还有未测混杂(PMID 34546296);未测混杂的敏感性可用贝叶斯方法给出”要多强的混杂才能把间接效应抹平”的定量边界(PMID 28882092)。25 人的膝骨关节炎试验给了盆冷水:加氡与不加氡,两组疼痛都持续下降、内源性大麻素 anandamide 都下降,氡无额外效应(PMID 33649972)——效应量可能小到中介分析根本做不出来。2026 年综述也承认,方案异质性与热、CO₂ 等共模因素让归因至今不成立(PMID 42340546)。
判决四件事:① 中介变量必须多点测(前、中、疗程末、随访),只测一次等于只测一个点;② “共有通道”与”氡增量”分开报,并报交互项;③ 免疫标志物不得当替代终点,非应答者也涨七倍就是反例;④ 先拟合衰减常数再看 p 值——两个指数项叠成的曲线,单点比较永远读错。
易学侧的一次对齐
中医讲”急则治标、缓则治本”,通常被理解成两种治法、两套药。放到这个场景里,它其实是在描述同一种干预在两个时间尺度上的两种读数:热是”标”,来得快、去得也快;免疫调节是”本”,启动慢、退得也慢。《素问·至真要大论》有一句更狠的话——”久而增气,物化之常也;气增而久,天之由也”,说的是同一种刺激长期同向施加,会从”调节”滑向”偏性”。这句话和上面第二层的双向调控是同一个意思:正常鼠被激活、病鼠被拉回正常,说明系统要的是回到中间,不是一路加码。古人对”疗程越长越好”的警惕,不是玄学禁忌,是对”调节系统在长期同向输入下会失去调节能力”的观察。
证据与局限
已验证:氡浴对疼痛的效应可持续至九个月(IMuRa,681 人);氡浴组 RANKL 下降与 Treg 上升为氡特有,热浴无此效应(RAD-ON02);含氡矿坑疗法后活性 TGF-β1 显著上升且应答者升幅更大;小鼠免疫激活需 4 周、2 周不显现。
部分验证:热效应半衰期、免疫效应半衰期均未在氡浴人群中被直接拟合,本文的双指数算术用的是量级假设而非实测参数;TGF-β1 是否参与镇痛链条,仅有相关性而无中介检验。
待验证:① 用限制性设计把两条衰减曲线拆开的实测;② 热×氡析因试验中交互项的方向与大小;③ Treg 在停疗后的回落时程,决定”长期效应”能否由它承载。
相关阅读
证据等级: B
参考文献: PMID 23864139, PMID 38292488, PMID 16810484, PMID 35400822, PMID 35203348, PMID 33649972, PMID 34546296, PMID 28882092, PMID 38872315, PMID 42340546
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Nine Months of Pain: Is It Still Heat or Has the Immune System Changed?
Evidence level: B
“Short-term efficacy and long-term efficacy” are not two snapshots of the same variable measured twice; they represent two decay curves differing by two orders of magnitude superimposed on one another. Without disentangling them, discussing mechanisms amounts to speculation.
Main Text
Conclusion First: In radon bath research, the two repeatedly cited metrics—the reduction in pain at the end of the course and the advantage persisting for nine months—are never two snapshots of the same event. They represent two curves overlaid on a single graph: one with an hourly half-life, the other with a monthly half-life. Reading them as a single curve inevitably leads to the illusion that “efficacy is slowly fading”; the true task is to fit the decay constants for each curve separately.
Layer 1: Heat Operates on an Hourly Clock. Thermal therapy acts quickly and wears off quickly; this is common sense, but “how quickly” has rarely been rigorously modeled. Methodologically, a caution is warranted: assessing the timeline of thermal adaptation cannot rely on pre-post comparisons at fixed time points, as baseline selection and decay model shapes directly alter conclusions (PMID 38872315). This pitfall is deeper in thermal analgesia—the effect of a single thermal exposure may vanish by half within a day, yet measurements are often taken only before and after the course, rendering the intermediate decay invisible.
Layer 2: Immunity Operates on a Weekly Clock. In mice inhaling 2,000 Bq/m³ radon, immune markers remained unchanged at 2 weeks but were activated at 4 weeks (Th1/Th2/Th17 balance remained intact), while splenic SOD decreased and CAT increased (PMID 35400822). The significance of “no change at 2 weeks, activation at 4 weeks” lies in the fact that immune pathways have a latency delay, while clinical courses typically last only 3 to 4 weeks, precisely straddling the onset threshold. Complicating matters further is the direction: in the same experiment, normal mice were activated while arthritis model mice (SKG) were pulled back to normal—regulation is bidirectional, directly negating the tracking logic that “higher levels of a specific marker are always better.” Another signal from the K/BxN model shifts focus: clinical score improvement accompanied by increased peripheral blood B cells and IL-5, not Tregs (PMID 35203348). Different models point to different cell types; this itself is evidence that the pathway is not yet defined.
Layer 3: One Arithmetic Calculation Can Determine Survival. Assume a half-life of 1 day for the thermal effect and 90 days for the immune effect. On day 30 post-treatment, thermal residual is $0.5^{30}$, approximately one billionth, effectively zero; immune residual is $0.5^{(30/90)}$, remaining at 79%. By day 180, immunity remains at 25%; by day 270, it drops to 12.5%. The IMuRa trial followed 681 patients for nine months, with pain and analgesic usage still significantly superior to controls (p=0.032 / p=0.007, PMID 23864139)—at nine months, thermal residual is already one billionth; the mere fact that it remains “significant” excludes the thermal effect without requiring any mediation analysis. The total effect measured at the end of the course contains a substantial share attributable to heat; this portion should not be expected to persist until the ninth month. The drop from 0.7 standard deviations to 0.2 should be correctly read as “the thermal component exiting on schedule,” not “efficacy is decaying.”
Layer 4: The Sharpest Cut. In 83 patients with ankylosing spondylitis treated at Bad Gastein for 3 to 4 weeks with low-dose radon mineral spring therapy, active TGF-β1 rose from 77 to 1,096 pg/ml. Stratifying by pain response, responders showed a 17-fold increase (96→1,654), while non-responders showed a 7-fold increase (53→402, PMID 16810484). Non-responders also increased seven-fold. If TGF-β1 were truly a mediator in the “radon → immunity → analgesia” chain, those without pain improvement should not show a similarly directional increase. Since it did rise, it suggests it is more of a concomitant response than the messenger link. Treating immune markers as surrogate endpoints will lead to failure here.
Layer 5: The Two-Arm Design Cannot Be Disassembled. The “radon bath vs. thermal bath” design appears clean, but radon must be delivered via thermal bath—heat is not a removable control but the carrier for radon. When the level of one factor depends on the existence of another, they constitute an interaction, not a mediation. Mediation analysis assumes additivity of paths; interaction explicitly states non-additivity. Performing mediation analysis on two-arm data defaults to the premise being questioned.
Layer 6: A Disassemblable Structure Has Emerged. In the RAD-ON02 trial, both thermal and radon baths reduced osteoclast differentiation and bone resorption area, with radon showing a more pronounced effect; however, only the radon bath group showed significant RANKL reduction and significant Treg increase, with no change in Th17 (PMID 38292488). The correct formulation is “shared thermal channel + radon-specific immune increment,” not “radon effective, thermal ineffective.” To test this, a factorial design of heat × radon is required; only factorial analysis can separate main effects from interaction terms.
Layer 7: True Mediation Requires Clarifying Timing First. Reporting standards require specifying causal hypotheses, measurement time points for mediators and outcomes, and whether unmeasured confounding exists between them (PMID 34546296); sensitivity to unmeasured confounding can be quantified using Bayesian methods to define the strength of confounding needed to wash out the indirect effect (PMID 28882092). A 25-person knee osteoarthritis trial offered a cold water basin: adding radon or not, pain declined continuously in both groups and endogenous anandamide decreased in both, with no additional effect from radon (PMID 33649972)—the effect size may be too small for mediation analysis to function. A 2026 review also acknowledges that protocol heterogeneity and common-mode factors like heat and CO₂ render attribution unproven to date (PMID 42340546).
Verdict on Four Matters: ① Mediators must be measured at multiple time points (pre, mid, end of course, follow-up); measuring once equals measuring only one point; ② Report “shared channel” and “radon increment” separately, including interaction terms; ③ Immune markers should not serve as surrogate endpoints, as the seven-fold rise in non-responders serves as a counterexample; ④ Fit decay constants before examining p-values—a curve composed of two exponential terms cannot be correctly read via single-point comparison.
Alignment from the Perspective of Yijing Studies
Traditional Chinese medicine posits “treat the manifestation in emergencies, treat the root in delays,” often understood as two distinct therapies and two sets of medicines. In this context, it actually describes two readings of the same intervention across two time scales: heat is the “manifestation,” arriving quickly and departing quickly; immune regulation is the “root,” starting slowly and receding slowly. Su Wen · Zhi Zhen Da Yao Lun contains a sharper statement—”prolonged application increases qi; this is the normal transformation of things; when qi increases and persists, this follows the way of heaven”—indicating that prolonged unidirectional application of a single stimulus shifts from “regulation” to “bias.” This aligns with the bidirectional regulation in Layer 2: normal mice were activated, while sick mice were pulled back to normal, indicating the system seeks a return to equilibrium rather than continuous escalation. The ancient caution against “the longer the course, the better” is not an esoteric taboo but an observation that “regulatory systems lose their capacity under long-term unidirectional input.”
Evidence and Limitations
Verified: Radon bath effects on pain persist up to nine months (IMuRa, 681 patients); RANKL reduction and Treg increase in the radon group are unique to radon, absent in thermal bath (RAD-ON02); active TGF-β1 significantly increased after radon mineral spring therapy with greater magnitude in responders; mouse immune activation requires 4 weeks, not apparent at 2 weeks.
Partially Verified: Half-lives for thermal and immune effects were not directly fitted in radon bath populations; the dual-exponential arithmetic used here relies on magnitude assumptions rather than empirical parameters; TGF-β1’s role in the analgesic chain shows correlation but lacks mediation testing.
To Be Verified: ① Empirical disentanglement of the two decay curves using restricted designs; ② Direction and magnitude of interaction terms in heat × radon factorial trials; ③ The回落 (rebound) timeline of Tregs post-treatment cessation, determining whether the “long-term effect” can be carried by them.
Related Reading
- Is Radon or the Hot Water Truly Effective in Radon Springs?
- From Low to High Radon Concentration: Is Analgesia Static, Gradual, or Inverted U-shaped?
- Can the Miner Model Be Directly Applied to Hot Spring Employees’ Radon Doses?
- Environment-Life Frequency Interface
Evidence Level: B
References: PMID 23864139, PMID 38292488, PMID 16810484, PMID 35400822, PMID 35203348, PMID 33649972, PMID 34546296, PMID 28882092, PMID 38872315, PMID 42340546
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply